Physical exercise-induced expression of inducible nitric oxide synthase and heme oxygenase-1 in human leukocytes: effects of RRR-alpha-tocopherol supplementation.
This study evaluated the effects of RRR-alpha-tocopherol (500 IU/day, 8 days) on in vivo cytokine response and cytoplasmic expression of inducible nitric oxide synthase (iNOS) and the antioxidant stress protein heme oxygenase-1 (HO-1) in human leukocytes after exhaustive exercise. Thirteen men were investigated in a double-blind, placebo-controlled, cross-over study with a wash-out period of 28 days. The exercise procedure consisted of an incremental treadmill test followed by a continuous run until exhaustion at 110% of the individual anaerobic threshold (total duration 28.5 +/- 0.8 min). HO-1 and iNOS protein were assessed in mono- (M), lympho-, and granulocytes (G) using flow cytometry. Plasma interleukin-6 (IL-6) and IL-8 were measured by ELISA. IL-6 rose significantly whereas IL-8 did not exhibit significant changes after exercise. Changes of IL-6 were not affected by RRR-alpha-tocopherol. Exercise induced an increase of iNOS protein primarily in M and G. A small, but significant, increase of HO-1 protein was measured in M and G. RRR-alpha-Tocopherol did not show any significant effects on cytoplasmic expression of iNOS and HO-1 at rest and after exercise. In conclusion, exhaustive exercise induces expression of iNOS and HO-1 in human leukocytes by a mechanism that is not sensitive to RRR-alpha-tocopherol supplementation.
Niess
A M
AM
Medical Clinic & Polyclinic, Department of Sports Medicine, University of Tuebingen, Germany. andreas.niess@uni-tuebingen.de
Sommer
M
M
Schneider
M
M
Angres
C
C
Tschositsch
K
K
Golly
I C
IC
Battenfeld
N
N
Northoff
H
H
Biesalski
H K
HK
Dickhuth
H H
HH
Fehrenbach
E
E
D000328:Adult; D015308:Anaerobic Threshold / Q000187:drug effects; D000975:Antioxidants / Q000008:administration & dosage / Q000494:pharmacology*; D004311:Double-Blind Method; D004790:Enzyme Induction / Q000187:drug effects; D015444:Exercise / Q000502:physiology*; D005080:Exercise Test; D005434:Flow Cytometry; D019084:Fluorescent Antibody Technique, Indirect; D006098:Granulocytes / Q000187:drug effects / Q000201:enzymology; D006419:Heme Oxygenase (Decyclizing) / Q000096:biosynthesis* / Q000235:genetics; D051547:Heme Oxygenase-1; D006801:Humans; D015850:Interleukin-6 / Q000097:blood; D016209:Interleukin-8 / Q000097:blood; D007962:Leukocytes / Q000187:drug effects / Q000201:enzymology*; D008214:Lymphocytes / Q000187:drug effects / Q000201:enzymology; D008297:Male; D008565:Membrane Proteins; D009000:Monocytes / Q000187:drug effects / Q000201:enzymology; D019001:Nitric Oxide Synthase / Q000096:biosynthesis* / Q000235:genetics; D052247:Nitric Oxide Synthase Type II; D012420:Running; D014810:Vitamin E / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*
D000975:Antioxidants; D015850:Interleukin-6; D016209:Interleukin-8; D008565:Membrane Proteins; D014810:Vitamin E; C496319:NOS2 protein, human; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; C496541:HMOX1 protein, human; D006419:Heme Oxygenase (Decyclizing); D051547:Heme Oxygenase-1